Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$47.1M
38M shares
52-week range
$1.13 – $3.95
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.63%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $243.0K | $17.2M | $44.8M | $52.3M | $25.2M |
| Cost of revenue | $387.0K | $1.7M | $94.4M | $0 | $5.3M |
| Gross profit | −$144.0K | $15.5M | −$49.6M | $52.3M | $19.9M |
| Gross margin | -59.3% | 89.9% | -110.9% | 100.0% | 78.9% |
| R&D | $14.5M | $43.1M | $94.4M | $109.2M | $94.4M |
| Operating income | −$23.9M | −$44.6M | −$78.5M | −$88.9M | −$96.0M |
| EBITDA | −$20.8M | −$39.2M | −$56.0M | −$78.2M | −$82.6M |
| Net income | −$21.4M | −$43.6M | −$68.3M | −$78.1M | −$87.9M |
| Net margin | -8823.9% | -253.4% | -152.5% | -149.3% | -348.5% |
| EPS (diluted) | -3.62 | -1.16 | -1.82 | -2.09 | -2.36 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-2.12 | $-2.33–$-1.91 | 2 |
| 2027 | $13M | $-1.57 | $-1.93–$-1.20 | 2 |
| 2028 | $20M | $-2.18 | $-3.32–$-0.98 | 1 |
| 2029 | $20M | $-1.95 | $-2.98–$-0.88 | 1 |
Forward consensus · source: Financial Modeling Prep
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
metagenomi.coNo one on the platform currently holds MGX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 787,900 | $1.1M |
No one on the platform has traded MGX yet.
| $52M |
| — |
| CNTBConnect Biopharma Holdings Limited | $2.19 | +5.80% | $138M | — |
| DTILPrecision BioSciences, Inc. | $7.29 | +8.00% | $94M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MGX faces a law-firm investigation over alleged fiduciary breaches by insiders.
View on StockTwits ↗$MGX 1.24$ so far today! Historic low 1.23$ New ATLs coming I gyess!
View on StockTwits ↗$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg
View on StockTwits ↗$MGX trash and pure management grift. Should be a university research department not a publicly traded company.
View on StockTwits ↗If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
View on StockTwits ↗$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM
View on StockTwits ↗$MGX 07:05 on Apr. 16 2026 Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems #tradeideas
View on StockTwits ↗$MGX Very underrated genome editing company. If MGX-001 works well in humans next year this will shoot right up.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.